![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from BENCHMRK-1 and -2
|
|
|
Reported by Jules Levin
Mike Miller1, Robert Danovich1, Signe Fransen2, Soumi Gupta2, Wei Huang2, Bach-Yen Nguyen1, Neil Parkin2, Christos Petropoulos2, Hedy Teppler1, Marc Witmer1, Jing Zhao1, and Daria Hazuda1.
Merck and Co.1, West Point, PA
and Monogram Biosciences2, S. San Francisco, CA
Copyright Merck & Co. Inc, Whithouse Station, New Jersey, USA, All rights Reserved
Update on resistance
Recent insights into mechanism of action
![MK-1.gif](../images/121008/MK-1.gif)
![eff-2.gif](../images/121008/eff-2.gif)
![long-3.gif](../images/121008/long-3.gif)
![benk-4.gif](../images/121008/benk-4.gif)
![q1-5.gif](../images/121008/q1-5.gif)
![ral-6.gif](../images/121008/ral-6.gif)
![rateVtr-7.gif](../images/121008/rateVtr-7.gif)
![even-8.gif](../images/121008/even-8.gif)
![et-9.gif](../images/121008/et-9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|